{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:36:22Z","timestamp":1794440182016,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,17]]},"DOI":"10.1038\/s41416-021-01417-7","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T05:03:14Z","timestamp":1622005394000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["The risk of contralateral breast cancer: a SEER-based analysis"],"prefix":"10.1038","volume":"125","author":[{"given":"Vasily","family":"Giannakeas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-0626","authenticated-orcid":false,"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-019-07628-w","volume":"26","author":"B Zhang","year":"2019","unstructured":"Zhang, B., Coopey, S. B., Gadd, M. A., Hughes, K. S., Chang, D. C. & Oseni, T. O. Trends in unilateral and contralateral prophylactic mastectomy use in ductal carcinoma in situ of the breast: patterns and predictors. Ann. Surg. Oncol. 26, 3863\u20133873 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","volume":"152","author":"R Nash","year":"2017","unstructured":"Nash, R., Goodman, M., Lin, C. C., Freedman, R. A., Dominici, L. S., Ward, K. et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012. JAMA Surg. 152, 648\u2013657 (2017).","journal-title":"JAMA Surg."},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamasurg.2020.0322","volume":"155","author":"T Wang","year":"2020","unstructured":"Wang, T., Baskin, A. & Dossett, L. A. Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 155, 759\u2013770 (2020).","journal-title":"JAMA Surg."},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-020-05965-z","volume":"185","author":"L Findlay-Shirras","year":"2021","unstructured":"Findlay-Shirras, L., Lima, I., Smith, G., Clemons, M. & Arnaout, A. Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study. Breast Cancer Res. Treat. 185, 517\u2013525 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR5","first-page":"CD002748","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine, N. E., Lostumbo, L., Wallace, J. & Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 4, CD002748 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1417_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong, S. M., Freedman, R. A., Sagara, Y., Aydogan, F., Barry, W. T. & Golshan, M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann. Surg. 265, 581\u2013589 (2017).","journal-title":"Ann. Surg."},{"key":"1417_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrclinonc.2014.3","volume":"11","author":"SA Narod","year":"2014","unstructured":"Narod, S. A. Bilateral breast cancers. Nat. Rev. Clin. Oncol. 11, 157\u2013166 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1417_CR8","doi-asserted-by":"publisher","unstructured":"Lim, D. W., Metcalfe, K. A. & Narod, S. A. Bilateral mastectomy in women with unilateral breast cancer: a review. JAMA Surg. https:\/\/doi.org\/10.1001\/jamasurg.2020.6664 (2021).","DOI":"10.1001\/jamasurg.2020.6664"},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"g226","DOI":"10.1136\/bmj.g226","volume":"348","author":"K Metcalfe","year":"2014","unstructured":"Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348, g226 (2014).","journal-title":"BMJ"},{"key":"1417_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-019-05182-3","volume":"175","author":"K Kaiser","year":"2019","unstructured":"Kaiser, K., Cameron, K. A., Beaumont, J., Garcia, S. F., Lacson, L., Moran, M. et al. What does risk of future cancer mean to breast cancer patients? Breast Cancer Res. Treat. 175, 579\u2013584 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/aje\/kwq481","volume":"173","author":"KC Cain","year":"2011","unstructured":"Cain, K. C., Harlow, S. D., Roderick, J. L., Nan, B., Yosef, M., Taffe, J. R. et al. Bias due to left truncation and left censoring in longitudinal studies of developmental and diseases processes. Am. J. Epidemiol. 173, 1078\u20131084 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"1417_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C., Vandenbroucke, J. P. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"1417_CR13","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen, Y., Thompson, W., Semenciw, R. & Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomark. Prev. 8, 855\u2013861 (1999).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1417_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-018-5031-4","volume":"173","author":"TI Yoon","year":"2019","unstructured":"Yoon, T. I., Kwak, B. S., Yi, O. V., Kim, S., Um, E., Yun, K. W. et al. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. Breast Cancer Res. Treat. 173, 657\u2013665 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22, 2328\u20132335 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10689-015-9825-9","volume":"14","author":"NN Basu","year":"2015","unstructured":"Basu, N. N., Ingham, S., Hodson, J., Lalloo, F., Bulman, M., Howell, A. et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam. Cancer 14, 531\u2013538 (2015).","journal-title":"Fam. Cancer"},{"key":"1417_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3747\/co.21.1656","volume":"21","author":"SA Narod","year":"2014","unstructured":"Narod, S. A., Tung, N., Lubinski, J., Huzarski, T., Robson, M., Lynch, H. T. et al. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Curr. Oncol. 21, 64\u201368 (2014).","journal-title":"Curr. Oncol."},{"key":"1417_CR18","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","volume":"28","author":"KE Malone","year":"2010","unstructured":"Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L. et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J. Clin. Oncol. 28, 2404\u20132410 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","volume":"34","author":"AJ van den Broek","year":"2016","unstructured":"van den Broek, A. J., van\u2019t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J. et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers. J. Clin. Oncol. 34, 409\u2013418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR20","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1002\/ijc.32918","volume":"146","author":"L Su","year":"2020","unstructured":"Su, L., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. Int. J. Cancer 146, 3335\u20133342 (2020).","journal-title":"Int. J. Cancer"},{"key":"1417_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","volume":"98","author":"L Mellemkjaer","year":"2008","unstructured":"Mellemkjaer, L., Dahl, C., Olsen, J. H., Bertelsen, L., Guldberg, P., Christensen, J. et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE study. Br. J. Cancer 98, 728\u2013733 (2008).","journal-title":"Br. J. Cancer"},{"key":"1417_CR22","unstructured":"National Comprehensive Cancer Network (NCCN). Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. V.2.2021. NCCN practice guidelines website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf (2021)."},{"key":"1417_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J. et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 3, 1190\u20131196 (2017).","journal-title":"JAMA Oncol."},{"key":"1417_CR24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2017.77.3424","volume":"36","author":"AS Reiner","year":"2018","unstructured":"Reiner, A. S., Sisti, J., John, E. M., Lynch, C. F., Brooks, J. D., Mellemkjaer, L. et al. Breast cancer family history and contralateral breast cancer risk in young women: an update from the Women\u2019s Environmental Cancer and Radiation Epidemiology Study. J. Clin. Oncol. 36, 1513\u20131520 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/cge.12604","volume":"89","author":"SA Narod","year":"2016","unstructured":"Narod, S. A., Kharazmi, E., Fallah, M., Sundquist, K. & Hemminki, K. The risk of contralateral breast cancer in daughters of women with and without breast cancer. Clin. Genet. 89, 332\u2013335 (2016).","journal-title":"Clin. Genet."},{"key":"1417_CR26","doi-asserted-by":"publisher","first-page":"djx051","DOI":"10.1093\/jnci\/djx051","volume":"109","author":"ME Robson","year":"2017","unstructured":"Robson, M. E., Reiner, A. S., Brooks, J. D., Concannon, P. J., John, E. M., Mellemkjaer, L. et al. Association of common genetic variants with contralateral breast cancer risk in the WECARE study. J. Natl Cancer Inst. 109, djx051 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"1417_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajhg.2020.09.001","volume":"107","author":"I Kramer","year":"2020","unstructured":"Kramer, I., Hooning, M. J., Mavaddat, N., Hauptmann, M., Keeman, R., Steyerberg, E. W. et al. Breast cancer polygenic risk score and contralateral breast cancer risk. Am. J. Hum. Genet. 107, 837\u2013848 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"1417_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/aje\/kwn422","volume":"169","author":"JA Knight","year":"2009","unstructured":"Knight, J. A., Bernstein, L., Largent, J., Capanu, M., Begg, C. B., Mellemkjaer, L. et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the Women\u2019s Environmental Cancer and Radiation Epidemiology study. Am. J. Epidemiol. 169, 962\u2013968 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"1417_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ijc.30791","volume":"141","author":"JA Knight","year":"2017","unstructured":"Knight, J. A., Fan, J., Malone, K. E., John, E. M., Lynch, C. F., Langballe, R. et al. Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE study. Int. J. Cancer 141, 916\u2013924 (2017).","journal-title":"Int. J. Cancer"},{"key":"1417_CR30","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/1055-9965.EPI-06-1003","volume":"16","author":"JA Largent","year":"2007","unstructured":"Largent, J. A., Capanu, M., Bernstein, L., Langholz, B., Mellemkaer, L., Malone, K. E. et al. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol. Biomark. Prev. 16, 906\u2013911 (2007).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1417_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1642-y","volume":"4","author":"JS Sisti","year":"2015","unstructured":"Sisti, J. S., Bernstein, L., Lynch, C. F., Reiner, A. S., Mellemkjaer, L., Brooks, J. D. et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. Springerplus 4, 825 (2015).","journal-title":"Springerplus"},{"key":"1417_CR32","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1002\/cam4.890","volume":"5","author":"JD Brooks","year":"2016","unstructured":"Brooks, J. D., John, E. M., Mellemkjaer, L., Lynch, C. F., Knight, J. A., Malone, K. E. et al. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. Cancer Med. 5, 3282\u20133291 (2016).","journal-title":"Cancer Med."},{"key":"1417_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10552-020-01284-2","volume":"31","author":"D Akdeniz","year":"2020","unstructured":"Akdeniz, D., Klaver, M. M., Smith, C. Z. A., Koppert, L. B. & Hooning, M. J. The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis. Cancer Causes Control. 31, 403\u2013416 (2020).","journal-title":"Cancer Causes Control."},{"key":"1417_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0948-4","volume":"20","author":"JA Knight","year":"2018","unstructured":"Knight, J. A., Blackmore, K. M., Fan, J., Malone, K. E., John, E. M., Lynch, C. F. et al. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Res. 20, 23 (2018).","journal-title":"Breast Cancer Res."},{"key":"1417_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao, X., Fisher, S. G. & Emami, B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int. J. Radiat. Oncol. Biol. Phys. 56, 1038\u20131045 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1417_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2016.05.010","volume":"63","author":"KC Aalders","year":"2016","unstructured":"Aalders, K. C., van Bommel, A. C. M., van Dalen, T., Sonke, G. S., van Diest, P. J., Boersma, L. J. et al. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur. J. Cancer 63, 118\u2013126 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1417_CR37","first-page":"181","volume":"7","author":"KR Davies","year":"2015","unstructured":"Davies, K. R., Cantor, S. B. & Brewster, A. M. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int. J. Women\u2019s Health 7, 181\u2013187 (2015).","journal-title":"Int. J. Women\u2019s Health"},{"key":"1417_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2018.03.011","volume":"39","author":"I Spronk","year":"2018","unstructured":"Spronk, I., Schellevis, F. G., Burgers, J. S., de Bock, G. H. & Korevaar, J. C. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast 39, 70\u201379 (2018).","journal-title":"Breast"},{"key":"1417_CR39","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1245\/s10434-017-5931-2","volume":"24","author":"ME Miller","year":"2017","unstructured":"Miller, M. E., Muhsen, S., Olcese, C., Patil, S., Morrow, M. & Van Zee, K. J. Contralateral breast cancer risk in women with ductal carcinoma in situ: is it high enough to justify bilateral mastectomy? Ann. Surg. Oncol. 24, 2889\u20132897 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-016-3973-y","volume":"159","author":"LE Elshof","year":"2016","unstructured":"Elshof, L. E., Schaapveld, M., Schmidt, M. K., Rutgers, E. J., van Leeuwen, F. E. & Wesseling, J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res. Treat. 159, 553\u2013563 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser, M. D., Weaver, D. L., Zhao, F., Worni, M., Grimm, L. J., Gulati, R. et al. Cancer outcomes in DCIS patients without locoregional treatment. J. Natl Cancer Inst. 111, 952\u2013960 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1417_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0874-x","volume":"19","author":"AS Reiner","year":"2017","unstructured":"Reiner, A. S., Lynch, C. F., Sisti, J. S., John, E. M., Brooks, J. D., Bernstein, L. et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res. 19, 83 (2017).","journal-title":"Breast Cancer Res."},{"key":"1417_CR43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J. et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320, 479\u2013484 (1989).","journal-title":"N. Engl. J. Med."},{"key":"1417_CR44","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135\u20131141 (2010).","journal-title":"Lancet Oncol."},{"key":"1417_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0726-0","volume":"18","author":"R Langballe","year":"2016","unstructured":"Langballe, R., Mellemkjaer, L., Mallone, K. E., Lynch, C. F., John, E. M., Knight, J. A. et al. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE study. Breast Cancer Res. 18, 65 (2016).","journal-title":"Breast Cancer Res."},{"key":"1417_CR46","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1417_CR47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805\u2013816 (2013).","journal-title":"Lancet"},{"key":"1417_CR48","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J. Clin. Oncol. 37, 423\u2013438 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR49","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.2007.16.0192","volume":"26","author":"MJ Hooning","year":"2008","unstructured":"Hooning, M. J., Aleman, B. M. P., Hauptmann, M., Baaijens, M. H. A., Klijn, J. G. M., Noyon, R. et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J. Clin. Oncol. 26, 5561\u20135568 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1417_CR50","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jnci\/djz010","volume":"111","author":"I Kramer","year":"2019","unstructured":"Kramer, I., Schaapveld, M., Oldenburg, H. S. A., Sonke, G. S., McCool, D., van Leeuwen, F. E. et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J. Natl Cancer Inst. 111, 709\u2013718 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1417_CR51","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10549-011-1820-8","volume":"131","author":"G Neta","year":"2012","unstructured":"Neta, G., Anderson, W. F., Gilbert, E. & Berrington, A. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER. Breast Cancer Res. Treat. 131, 1021\u20131027 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.bjc.6605435","volume":"102","author":"A Berrington de Gonzalez","year":"2010","unstructured":"Berrington de Gonzalez, A., Curtis, R. E., Gilbert, E., Berg, C. D., Smith, S. A., Stovall, M. et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br. J. Cancer 102, 220\u2013226 (2010).","journal-title":"Br. J. Cancer"},{"key":"1417_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-20301-6_3","volume":"1152","author":"CG Yedjou","year":"2019","unstructured":"Yedjou, C. G., Sims, J. N., Miele, L., Noubissi, F., Lowe, L., Fonseca, D. D. et al. Health and racial disparity in breast cancer. Adv. Exp. Med. Biol. 1152, 31\u201349 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1417_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/82533","volume":"26","author":"J Peto","year":"2000","unstructured":"Peto, J. & Mack, T. M. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 26, 411\u2013414 (2000).","journal-title":"Nat. Genet."},{"key":"1417_CR55","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/82495","volume":"26","author":"D Easton","year":"2000","unstructured":"Easton, D. Breast cancer\u2013not just whether but when? Nat. Genet. 26, 390\u2013391 (2000).","journal-title":"Nat. Genet."},{"key":"1417_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","volume":"24","author":"KK Hunt","year":"2017","unstructured":"Hunt, K. K., Euhus, D. M., Boughey, J. C., Chagpar, A. B., Feldman, S. M., Hansen, N. M. et al. Society of Surgical Oncology Breast Disease Working Group statement on prophylactic (risk-reducing) mastectomy. Ann. Surg. Oncol. 24, 375\u2013397 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/SLA.0000000000002309","volume":"267","author":"FC Wright","year":"2018","unstructured":"Wright, F. C., Look Hong, N. J., Quan, M. L., Beyfuss, K., Temple, S., Covelli, A. et al. Indications for contralateral prophylactic mastectomy: a consensus statement using modified Delphi methodology. Ann. Surg. 267, 271\u2013279 (2018).","journal-title":"Ann. Surg."},{"key":"1417_CR58","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey, J. C., Attai, D. J., Chen, S. L., Cody, H. S., Dietz, J. R., Feldman, S. M. et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann. Surg. Oncol. 23, 3100\u20133105 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR59","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2021. NCCN practice guidelines website. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (2021)."},{"key":"1417_CR60","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1245\/s10434-014-4033-7","volume":"22","author":"AM Covelli","year":"2015","unstructured":"Covelli, A. M., Baxter, N. N., Fitch, M. I., McCready, D. R. & Wright, F. C. \u2018Taking control of cancer\u2019: understanding women\u2019s choice for mastectomy. Ann. Surg. Oncol. 22, 383\u2013391 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR61","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1245\/s10434-011-1914-x","volume":"18","author":"A Abbott","year":"2011","unstructured":"Abbott, A., Rueth, N., Pappas-Varco, S., Kuntz, K., Kerr, E. & Tuttle, T. Perceptions of contralateral breast cancer: an overestimation of risk. Ann. Surg. Oncol. 18, 3129\u20133136 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR62","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1245\/s10434-015-4442-2","volume":"22","author":"PR Portschy","year":"2015","unstructured":"Portschy, P. R., Abbott, A. M., Burke, E. E., Nzara, R., Marmor, S., Kuntz, K. M. et al. Perceptions of contralateral breast cancer risk: a prospective, longitudinal study. Ann. Surg. Oncol. 22, 3846\u20133852 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"1417_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"13","author":"NN Basu","year":"2015","unstructured":"Basu, N. N., Ross, G. L., Evans, D. G. & Barr, L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J. Surg. Oncol. 13, 237 (2015).","journal-title":"World J. Surg. Oncol."},{"key":"1417_CR64","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-018-4763-5","volume":"170","author":"M Chowdhury","year":"2018","unstructured":"Chowdhury, M., Euhus, D., Arun, B., Umbricht, C., Biswas, S. & Choudhary, P. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res. Treat. 170, 415\u2013423 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"1417_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1221-1","volume":"21","author":"D Giardiello","year":"2019","unstructured":"Giardiello, D., Steyerberg, E. W., Hauptmann, M., Adank, M. A., Akdeniz, D., Blomqvist, C. et al. Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Res. 21, 144 (2019).","journal-title":"Breast Cancer Res."},{"key":"1417_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-020-05611-8","volume":"181","author":"D Giardiello","year":"2020","unstructured":"Giardiello, D., Hauptmann, M., Steyerberg, E. W., Adank, M. A., Akdeniz, D., Blom, J. C. et al. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Res. Treat. 181, 423\u2013434 (2020).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01417-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:03:40Z","timestamp":1653509020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01417-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8,17]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01417-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is exempt from informed patient consent and board approval by the Women\u2019s College Hospital Ethics Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data relevant to the study are included in the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"S.A.N. is an editorial board member of BJC. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"V.G. is supported by the Canadian Institutes of Health Research (CIHR) Frederick Banting & Charles Best Canada Graduate Scholarship Doctoral Research Award. D.W.L. is supported by the CIHR Fellowship, the Helen Marion Walker\u2014Soroptimist Women\u2019s Health Research Scholarship and the Canadian Cancer Society Chair in Breast Cancer Research at Women\u2019s College Research Institute at Women\u2019s College Hospital. S.A.N. is the recipient of the Tier I Canada Research Chair in Breast Cancer. This work was supported by the Peter Gilgan Centre for Women\u2019s Cancers at Women\u2019s College Hospital, in partnership with the Canadian Cancer Society.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}